AstraZeneca (NYSE:AZN – Get Free Report) and Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.
Institutional and Insider Ownership
20.4% of AstraZeneca shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for AstraZeneca and Iterum Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AstraZeneca | 0 | 3 | 16 | 0 | 2.84 |
| Iterum Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
AstraZeneca currently has a consensus price target of $206.67, indicating a potential upside of 11.91%. Given AstraZeneca’s stronger consensus rating and higher possible upside, research analysts clearly believe AstraZeneca is more favorable than Iterum Therapeutics.
Profitability
This table compares AstraZeneca and Iterum Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AstraZeneca | 17.68% | 31.85% | 13.62% |
| Iterum Therapeutics | N/A | N/A | -65.54% |
Valuation and Earnings
This table compares AstraZeneca and Iterum Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AstraZeneca | $62.38 billion | 4.59 | $10.22 billion | $7.07 | 26.12 |
| Iterum Therapeutics | $390,000.00 | 4.10 | -$24.77 million | ($0.75) | -0.04 |
AstraZeneca has higher revenue and earnings than Iterum Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
AstraZeneca has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.96, meaning that its share price is 196% more volatile than the S&P 500.
Summary
AstraZeneca beats Iterum Therapeutics on 12 of the 14 factors compared between the two stocks.
About AstraZeneca
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
About Iterum Therapeutics
Iterum Therapeutics plc (NASDAQ:ITRM) is an Ireland-based pharmaceutical company focused on developing and commercializing anti-infective therapies for infections caused by drug-resistant bacteria. The company’s lead product is sulopenem, a penem-class antibiotic designed to provide activity against a broad range of pathogens. In 2024, the U.S. Food and Drug Administration approved Orlynvah, an oral combination of sulopenem etzadroxil and probenecid, for the treatment of uncomplicated urinary tract infections in adult women when alternative oral antibacterial treatments are not suitable.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
